Ofir Levi - 14 May 2021 Form 4 Insider Report for Vallon Pharmaceuticals, Inc. (GRI)

Role
Director
Signature
/s/ David Baker, attorney-in-fact
Issuer symbol
GRI
Transactions as of
14 May 2021
Net transactions value
$0
Form type
4
Filing time
18 May 2021, 16:08:07 UTC

Sponsored

Quoteable Key Fact

"Ofir Levi filed Form 4 for Vallon Pharmaceuticals, Inc. (GRI) on 18 May 2021."

Quick Takeaways

  • This page summarizes Ofir Levi's Form 4 filing for Vallon Pharmaceuticals, Inc. (GRI).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Filing timestamp: 18 May 2021, 16:08.

What Changed

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRI Stock Option (Right to Buy) Award $0 +15,000 $0.000000 15,000 14 May 2021 Common Stock 15,000 $3.66 Direct F1
transaction GRI Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 14 May 2021 Common Stock 30,000 $3.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021.
F2 The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant.